Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03631225 · ClinicalTrials.gov registry record
The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis
A clinical trial of Rheumatoid Arthritis (RA), sponsored by Sequenom.
- Active
- Registry status
- 1,500
- Enrollment target
- 20
- Study locations
NCT03631225 is a study of Rheumatoid Arthritis (RA) that is active but no longer recruiting, run by Sequenom. The registered enrollment target is 1,500 participants, above the 180-participant average among 17 other Rheumatoid Arthritis (RA) trials with a reported enrollment target (733% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT03631225, a study of Rheumatoid Arthritis (RA), is active but no longer recruiting, sponsored by Sequenom.
- ACTIVE NOT RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of treating patients diagnosed with rheumatoid arthritis (RA) is to achieve remission or low disease activity and thereby prevent joint damage, loss of physical function, and disability. Optimal management requires regular assessment of disease activity, with treatment changes made as needed for optimal efficacy. Vectra is a blood serum test that looks at 12 biomarkers and produces a score on a scale of 1 to 100. The Vectra score has been shown to be the strongest predictor of risk for progression of disease. There is opportunity to gain more information about the utility of Vectra in a real-world clinical setting. This study will, therefore, evaluate the utility of Vectra for guiding treatment decisions and improving RA-related outcomes in comparison with usual care, which will not include Vectra testing. This study will enable a direct evaluation of the clinical benefit associated with using Vectra to guide treatment decisions in patients with RA.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Vectra
Study Locations (20)
Florida
- AARDS Research, Inc. - Aventura
- Robert W. Levin, MD, PA - Clearwater
- Artemisa Analytics - Miami
- Rheumatology Associates of Central Florida, P.A. - Orlando
- Clin-Med Research & Development, LLC - South Miami
Pennsylvania
- East Penn Rheumatology Associates, P.C. - Bethlehem
- Altoona Center for Clinical Research - Duncansville
- Advanced Rheumatology & Arthritis Research Center, PC - Wexford
- PA Regional Center for Arthritis and Osteoporosis Research - Wyomissing
California
- Bio Solutions Clinical Research - La Mesa
- Brigid Freyne, MD - Murrieta
- J. Lee MD Medical Corp - Orange
Louisiana
- Accurate Clinical Research - Lake Charles
- Arthritis and Diabetes Clinic, Inc. - Monroe
Ohio
- Paramount Medical Research & Consulting, LLC - Middleburg Heights
- Southern Ohio Rheumatology Inc. - Wheelersburg
Delaware
- Delaware Arthritis - Lewes
Mississippi
- North Mississippi Medical Center - Tupelo
Missouri
- Clinvest Research, LLC. - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2019-06-25 |
| Est. Completion | 2026-04-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03631225
The ClinicalTrials.gov registry entry for NCT03631225 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 180-participant average among 17 other Rheumatoid Arthritis (RA) trials with a reported enrollment target (733% higher). The listed sponsor is Sequenom, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis (RA) appearing as the primary indexed condition, and to 1 intervention - of which Vectra is the first listed.
NCT03631225 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT03631225 about?
NCT03631225 is a clinical study titled "The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis". The goal of treating patients diagnosed with rheumatoid arthritis (RA) is to achieve remission or low disease activity and thereby prevent joint damage, loss of physical function, and disability. Optimal management requires regular assessment of disease activity, with treatment changes made as neede...
What is the current status of trial NCT03631225?
This trial is currently active not recruiting. The enrollment target is 1,500 participants. The study started on 2019-06-25. Estimated completion is 2026-04-15.
What conditions does trial NCT03631225 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis (RA).
What interventions are being tested in trial NCT03631225?
The interventions under investigation include: Vectra (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03631225?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03631225 being conducted?
This trial has 20 study locations across California, Delaware, Florida, Louisiana, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis (RA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]
RECRUITING · NA
-
Probiotics in Adults With Rheumatoid Arthritis
RECRUITING · NA
-
Dose Response of Exercise for Arthritis Management
RECRUITING · NA
-
A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
-
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.